抗血小板治疗新靶点治疗急性冠脉综合征的研究进展
Research progress on new antiplatelet therapeutic targets for the treatment of acute coronary syndrome
刘强 1任艳琴2
作者信息
- 1. 山西医科大学汾阳学院,汾阳 032200,山西
- 2. 山西医科大学汾阳学院,汾阳 032200,山西;山西医科大学附属汾阳医院,汾阳 032200,山西
- 折叠
摘要
急性冠脉综合征(ACS)是一种由于冠状动脉内不稳定的粥样硬化斑块破裂或糜烂导致血栓形成的心脏急性缺血综合征.抗血小板治疗是治疗ACS的关键策略,尽管当前已取得一定成功,但仍存在局限性,如血栓复发和出血等副作用,这限制了药物的长期使用.未来的抗血小板治疗可能通过针对参与血小板功能的新型靶点的拮抗作用,实现更有效或更安全的治疗方法.本文重点介绍了具有潜力的靶点抑制剂,包括糖蛋白Ⅵ(glycoprotein Ⅵ,GPⅥ)、蛋白酶激活受体(PAR)-4、GPIb、5-羟色胺受体亚型 2A(5-HT2A)、蛋白二硫异构酶、p选择素和磷酸肌醇3-激酶β的抑制剂.
Abstract
Acute coronary syndrome(ACS)is a cardiac acute ischemic syndrome caused by the rupture or erosion of unstable atherosclerotic plaques within the coronary artery,leading to thrombus formation.Antiplatelet therapy is a key strategy in treating ACS,and although some suc-cess has been achieved,there are still limitations,such as thrombus recurrence and bleeding side ef-fects,which limit the long-term use of drugs.Fu-ture antiplatelet therapies may achieve more effec-tive or safer treatment methods by targeting novel targets involved in platelet function.This article fo-cuses on potential target inhibitors,including GPVI,protease-activated receptor(PAR)-4,GPIb,5-hy-droxytryptamine receptor subtype 2A(5-HT2A),protein disulfide isomerase,P-selectin,and phos-phatidylinositol 3-kinase β inhibitors.
关键词
急性冠脉综合征/抗血小板治疗/出血/药物Key words
acute coronary syndrome/antiplate-let therapy/bleeding/medication引用本文复制引用
基金项目
山西省卫生健康委科研课题(2023017)
出版年
2023
国家科技期刊平台
NSTL
维普
万方数据